The quarter cleared both the outside bar and Elanco’s own outlook. Adjusted EPS of $0.34 exceeded the published consensus of about $0.27, while revenue of $1.368 billion topped the roughly $1.31 billion expectation. It also surpassed the company’s prior Q2 ranges for revenue ($1.300-$1.325 billion), adjusted EBITDA ($240-$260 million) and adjusted EPS ($0.25-$0.28). The result was not just accounting-driven: organic constant-currency revenue rose 8%, led by 11% Pet Health growth and 12% cattle growth. (Second Quarter Results; Financial Guidance)
| Metric | Q2 2026 actual | Q2 2025 | Prior company Q2 outlook / published expectation |
|---|---|---|---|
| Revenue | $1.368B | $1.241B | $1.300-$1.325B / ~$1.31B consensus (Second Quarter Results; Financial Guidance) |
| Organic constant-currency revenue growth | 8% | — | 4%-6% prior outlook (Second Quarter Results; Q2 Guidance) |
| Adjusted EBITDA | $288M | $238M | $240-$260M prior outlook (Adjusted EBITDA reconciliation; Q2 Guidance) |
| Adjusted EBITDA margin | 21.2% | 19.2% | — (Adjusted EBITDA reconciliation) |
| Adjusted EPS | $0.34 | $0.26 | $0.25-$0.28 prior outlook / ~$0.27 consensus (Adjusted EPS reconciliation; Q2 Guidance) |
| Full-year revenue guidance | $5.090-$5.140B | — | Raised from $5.010-$5.085B (2026 Full Year Guidance) |
| Full-year adjusted EBITDA guidance | $1.010-$1.035B | — | Raised from $975M-$1.005B (2026 Full Year Guidance) |
| Full-year adjusted EPS guidance | $1.10-$1.16 | — | Raised from $1.03-$1.09 (2026 Full Year Guidance) |
The guidance raise makes the beat more consequential. Full-year revenue guidance rose $67.5 million at the midpoint, adjusted EBITDA rose $32.5 million, and adjusted EPS rose $0.07. Importantly, the company lifted its underlying organic-growth floor to 6%-7% from 5%-7%, rather than relying only on the approximately $60 million foreign-exchange tailwind; expected adjusted gross-margin expansion also improved to 50 basis points from 40 basis points. (2026 Full Year Guidance)
Margins and deleveraging strengthened alongside growth. Adjusted gross margin expanded 80 basis points year over year in Q2, ahead of management’s own expectation, while adjusted EBITDA margin expanded 200 basis points. Net debt fell to $3.159 billion from $3.335 billion at March 31, and net leverage reached 3.1x from 3.5x. That addresses a key standing concern for a company still carrying substantial debt. (Adjusted Gross Profit reconciliation; Adjusted EBITDA reconciliation; Net Debt reconciliation)
The main qualification is that adjusted profit remains far above GAAP profit, and spending is rising. GAAP EPS was only $0.11, versus $0.34 adjusted, with intangible amortization alone accounting for $0.27 per share of exclusions. Marketing, selling and administrative expense rose 12%, and Elanco expects Q3 operating expenses to increase about 10% in constant currency as it funds product launches. Those costs are deliberate growth investment, but they mean the improved margin trajectory must continue to offset higher commercial spending. (Income Statement; Adjusted EPS reconciliation; Third Quarter Guidance)
Read the original 8-K on SEC EDGAR ↗